Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

use it is minimally excreted in the kidneys, betrixaban may be the only drug of its kind available for the large and growing population of moderately and severely renally-impaired patients who are at high risk for bleeding. This would dramatically expand the treatment index for this type of drug."

Betrixaban has been specifically designed to have ideal properties for chronic therapy and to be the only true, once-daily oral anticoagulant with distinct advantages over other currently available anticoagulants or those in clinical trials such as rivaroxaban, apixaban and dabigatran.

Betrixaban inhibits Factor Xa, a validated target for which there are approved drugs on the market. Inhibiting Factor Xa activity appears to offer advantages over other anticoagulation targets. Portola believes betrixaban will offer several key differentiating features including a long half-life and a low peak-to-trough drug concentration ratio to support once-daily dosing and the potential for an improved benefit/risk profile. Betrixaban is minimally excreted through the kidneys and therefore, unlike other novel agents, may not require dose adjustment in patients with moderately impaired renal function and may be the only novel oral anticoagulant available for patients with severe renal disease. And because betrixaban is neither an inhibitor nor an inducer of cytochrome P450 enzymes, it minimizes the risk of drug-drug interactions often seen with other Factor Xa inhibitors in development and with warfarin.

Portola has completed EXPERT, a 200-patient Phase II trial, demonstrating betrixaban's clinical proof of concept in preventing venous thromboembolism in patients undergoing knee replacement surgery. Preclinical and Phase I studies, in addition to EXPERT, have shown that betrixaban is well tolerated over a range of dose levels.

Portola may develop betrixaban for additional indications including prevention of venous thromboembolism (VTE) in medically ill patients
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clinverse, Inc. , a ... trials, announced today it has formed a strategic ... ClinPay® FLS eClinical commerce platform aggregates data collected ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship product, ... reporting transfer of value at investigator meetings or ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... Bed bugs have become so widespread in the past ... to chemical-based pesticides for help to completely get rid of ... solutions present, the company advised the public to kill ... According to My Cleaning Products, chemical-based pesticides are not as ... shared that the pests have already developed immunity to the ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... Ohio,s strengths in the polymer industry ... fields to spark biomedical innovation, COLUMBUS, Ohio, Nov. ... biomedical research, commercialization and innovation after the,recent launch of ... Ohio Business Development Coalition, the nonprofit,organization that markets the ...
... Medical Sciences, Providers of Inactivated Polio Vaccine (IPV) ... ... PARIS, November 12 Sanofi Pasteur, the,vaccines division of sanofi-aventis ... from Sanofi Pasteur for primary,immunization of all infants. The IPV ...
... getting smaller and smaller. And as hand-held devices from ... get more powerful, the race is on to develop memory ... on tiny formats. , Researchers at The University of Nottingham ... carbon nanotubes to create a cheap and compact memory cell ...
Cached Biology Technology:Ohio Becoming Global Hub for Biomedical Research and Commercialization 2Ohio Becoming Global Hub for Biomedical Research and Commercialization 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6Miniaturizing memory: Taking data storage to the molecular level 2
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
(Date:5/22/2013)... (May 22, 2013)The omega 3 fatty acids in fish ... diseaseso much so that the American Heart Association currently ... week, particularly fatty varieties rich in omega 3s. However, ... mystery. In a new study, scientists led by Jason ... this phenomenon by providing evidence that fish oil might ...
(Date:5/22/2013)... DNA can endanger the whole organism, as they may ... (LMU) in Munich now report how byproducts of respiration ... The DNA in our cells controls the form and ... instructions for this are encoded in the linear sequence ... adenine (A), cytosine (C), guanine (G) and thymine (T). ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2
... CORVALLIS, Ore. As wolf populations grow in parts of ... value in aiding broader ecosystem recovery but a new ... could play an important role in helping to save other ... Bulletin, scientists suggest that a key factor in the Canada ...
... asthmatic children, on their exposure to molds or dampness in ... C has greater or smaller beneficial effect against asthma, according ... Proposals that vitamin C might be beneficial in the treatment ... from controlled trials have been conflicting., Drs Mohammed Al-Biltagi from ...
... the world,s strangest animals a unique fish that lives on ... has a rich and complex social life, a new study has ... arnoldorum ) has been detailed for the first time in research ... to colonise the land., The Pacific leaping blenny is a marine ...
Cached Biology News:Wolves may aid recovery of Canada lynx, a threatened species 2Landlubber fish leap for love when tide is right 2
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: